Skip to main content
. 2019 Jan 7;133(12):1313–1324. doi: 10.1182/blood-2018-09-871418

Figure 3.

Figure 3.

Novel targets of aberrant somatic hypermutation in BL. Noncoding mutation peaks overlapping (A) the PVT1 promoter region and (B) a distal PAX5 enhancer. Mutations from the BL discovery cohort (N = 106) and a DLBCL cohort (N = 153) are shown separately.